key: cord-0824842-lvvxbxph
authors: David, Alessia; Parkinson, Nicholas; Peacock, Thomas P; Pairo-Castineira, Erola; Khanna, Tarun; Cobat, Aurelie; Tenesa, Albert; Sancho-Shimizu, Vanessa; Casanova, Jean-Laurent; Abel, Laurent; Barclay, Wendy S.; Baillie, J. Kenneth; Sternberg, Michael JE
title: A common TMPRSS2 variant has a protective effect against severe COVID-19
date: 2022-01-10
journal: Curr Res Transl Med
DOI: 10.1016/j.retram.2022.103333
sha: 7610bc0c34fb197aac4895a681b24a70cf128384
doc_id: 824842
cord_uid: lvvxbxph

BACKGROUND: : The human protein transmembrane protease serine type 2 (TMPRSS2) plays a key role in SARS-CoV-2 infection, as it is required to activate the virus’ spike protein, facilitating entry into target cells. We hypothesized that naturally-occurring TMPRSS2 human genetic variants affecting the structure and function of the TMPRSS2 protein may modulate the severity of SARS-CoV-2 infection. METHODS: : We focused on the only common TMPRSS2 non-synonymous variant predicted to be damaging (rs12329760 C>T, p.V160M), which has a minor allele frequency ranging from from 0.14 in Ashkenazi Jewish to 0.38 in East Asians. We analysed the association between the rs12329760 and COVID-19 severity in 2,244 critically ill patients with COVID-19 from 208 UK intensive care units recruited as part of the GenOMICC (Genetics Of Mortality In Critical Care) study. Logistic regression analyses were adjusted for sex, age and deprivation index. For in vitro studies, HEK293 cells were co-transfected with ACE2 and either TMPRSS2 wild type or mutant (TMPRSS2(V160M)). A SARS-CoV-2 pseudovirus entry assay was used to investigate the ability of TMPRSS2(V160M) to promote viral entry. RESULTS: : We show that the T allele of rs12329760 is associated with a reduced likelihood of developing severe COVID-19 (OR 0.87, 95%CI:0.79-0.97, p=0.01). This association was stronger in homozygous individuals when compared to the general population (OR 0.65, 95%CI:0.50-0.84, p=1.3 × 10(−3)). We demonstrate in vitro that this variant, which causes the amino acid substitution valine to methionine, affects the catalytic activity of TMPRSS2 and is less able to support SARS-CoV-2 spike-mediated entry into cells. CONCLUSION: : TMPRSS2 rs12329760 is a common variant associated with a significantly decreased risk of severe COVID-19. Further studies are needed to assess the expression of TMPRSS2 across different age groups. Moreover, our results identify TMPRSS2 as a promising drug target, with a potential role for camostat mesilate, a drug approved for the treatment of chronic pancreatitis and postoperative reflux esophagitis, in the treatment of COVID-19. Clinical trials are needed to confirm this.

The human protein transmembrane protease serine type 2 (TMPRSS2) plays a key role in SARS-CoV-2 infection, as it is required to activate the virus' spike protein, facilitating entry into target cells. We hypothesized that naturally-occurring TMPRSS2 human genetic variants affecting the structure and function of the TMPRSS2 protein may modulate the severity of SARS-CoV-2 infection.

We focused on the only common TMPRSS2 non-synonymous variant predicted to be damaging (rs12329760 C>T, p.V160M), which has a minor allele frequency ranging from from 0.14 in Ashkenazi Jewish to 0.38 in East Asians. We analysed the association between the rs12329760 and COVID-19 severity in 2,244 critically ill patients with COVID-19 from 208 UK intensive care units recruited as part of the GenOMICC (Genetics Of Mortality In Critical Care) study. Logistic regression analyses were adjusted for sex, age and deprivation index. For in vitro studies, HEK293 cells were co-transfected with ACE2 and either TMPRSS2 wild type or mutant (TMPRSS2 V160M ). A SARS-CoV-2 pseudovirus entry assay was used to investigate the ability of TMPRSS2 V160M to promote viral entry.

We show that the T allele of rs12329760 is associated with a reduced likelihood of developing severe COVID-19 (OR 0.87, 95%CI:0.79-0.97, p=0.01). This association was stronger in homozygous individuals when compared to the general population (OR 0.65, 95%CI:0.50-0.84, p=1.3×10 -3 ). We demonstrate in vitro that this variant, which causes the amino acid substitution valine to methionine, affects the catalytic activity of TMPRSS2 and is less able to support SARS-CoV-2 spike-mediated entry into cells.

TMPRSS2 rs12329760 is a common variant associated with a significantly decreased risk of severe COVID-19. Further studies are needed to assess the expression of TMPRSS2 across different age groups. Moreover, our results identify TMPRSS2 as a promising drug target, with a potential role for camostat mesilate, a drug approved for the treatment of chronic pancreatitis and postoperative reflux esophagitis, in the treatment of COVID-19. Clinical trials are needed to confirm this.

The severe acute respiratory syndrome like coronavirus (SARS-CoV-2) has infected over 190 million individuals globally and has caused more than 4.2 million deaths as of August 2021 (1) . SARS-CoV-2 infection has a broad clinical spectrum, ranging from asymptomatic or mildly symptomatic, to a life-threatening presentation requiring admission to intensive care.

Age, and to a much lesser extent male gender and various underlying clinical conditions, such as cardiovascular disease, obesity and diabetes, are known risk factors associated with an increased COVID-19 morbidity and mortality (2) (3) . The role of an individual's genetic background has recently emerged as an additional, yet not clearly understood, risk factor for COVID-19 (4)(5) (6) . Rare genetic variants in genes involved in the regulation of type I interferon (IFN) immunity, including autosomal recessive IRF7 and IFNAR1 deficiencies, have been identified in patients with life-threatening COVID-19 (6) . Autoantibodies to type I IFNs also account for at least 10% of cases of critical COVID-19 pneumonia (7) . Genomewide association studies (GWAS) have discovered genetic haplotypes spanning several genes that are associated with COVID-19 severity (3) (4) (8) .

The transmembrane protease serine type 2 (TMPRSS2) protein plays a key role in coronavirus infections, (9)(10)(11) , including SARS-CoV-2, as it is required for priming the virus' spike (S) glycoprotein through its cleavage, thus facilitating endosome-independent entry into target cells (12) (13) . TMPRSS2, which is part of the type 2 transmembrane serine protease (TTSP) family, is characterized by androgen receptor elements located upstream to its transcription site (14) . As well as cleaving and activating viral glycoproteins of coronaviruses and influenza A and B viruses (15) , TMPRSS2 is subject to autocleavage, which results in the liberation of its soluble catalytic domain (16) . The conditions under which autocleavage of TMPRSS2 and other members of the TTSPs family occurs are yet to be elucidated.

TMPRSS2 is expressed in lung and bronchial cells (17) , but also in the colon, stomach, pancreas, salivary glands and numerous other tissues (18) . Moreover, it is co-expressed in bronchial and lung cells with the angiotensin-converting enzyme 2 (ACE2) (17) , which is the best described SARS-CoV-2 cellular receptor (19) . In the olfactory epithelium of mice, the expression of TMPRSS2, but not ACE2, appears to be age-related and greater in older compared to younger animals (20) . Similarly, a recent study showed that expression of TMPRSS2 in mouse and human lung tissue is also age-related (21) . Studies in TMPRSS2 knock out (KO) mice reported reduced SARS-CoV and MERS-CoV replication in the lungs compared to wild-type mice, and a reduced proinflammatory viral response, especially cytokine and chemokine release via the Toll-like receptor 3 pathway (22) (23) . We have recently shown that TMPRSS2 expression permits cell surface entry of SARS-CoV-2, allowing the virus to bypass potent endosomal restriction factors (24) . In vitro studies have shown that TMPRSS2 inhibitors prevent primary airway cell and organoid infection by SARS-CoV and SARS-CoV-2 (25) , (24) , (26) . In animal studies, mice infected with SARS-CoV and treated with the serine protease inhibitor camostat mesilate had a high survival rate (27) . Recently, camostat mesilate (which, in Japan, is already approved for patients with chronic pancreatitis and postoperative reflux esophagitis) was shown to block SARS-CoV-2 lung cell infection in vitro (12) (24) . Furthermore, camostat mesylate and its metabolite GBPA have been shown to block SARS-CoV-2 spread in human lung tissue ex vivo (28) .

Several clinical trials using camostate in COVID-19 patients are currently underway (29) .

In view of the data from animal models and cell-based studies supporting a protective role of a knock out TMPRSS2 on coronavirus infection (including SARS and MERS), we hypothesized that naturally-occurring TMPRSS2 genetic variants affecting the structure and function of the TMPRSS2 protein may modulate the severity of SARS-CoV-2 infection.

The recently released 3D structure of TMPRSS2 (PDB: 7meq) was used to assess the impact missense variants. The Phyre homology modelling algorithm (30) was used to resolve missing amino acid regions in the SRSC domain that were not experimentally solved (described in Supplementary material). The FASTA sequence of TMPRSS2 was obtained from the UniProt protein knowledge database (31) (UniProt Id O15393, corresponding to 492 amino acid transcript Ensembl ID ENST00000332149.10). The recently released AlphaFold model (32) was compared to the Phyre model. The impact of each missense variant on the TMPRSS2 protein structure was assessed by analysing the following 16 features, using our in-house algorithm Missense3D (33): breakage of a disulfide bond, hydrogen bond or salt bridge, introduction of a buried proline, clash, introduction of hydrophilic residue, introduction of a buried charged residue, charge switch in a buried residue, alteration in secondary structure, replacement of a charged with uncharged buried residue, introduction of a disallowed phi/psi region, replacement of a buried glycine with any other residue, alteration in a cavity, replacement of cis proline, buried to exposed residue switch, replacement of a glycine located in a bend. In addition, we used the SIFT (34) and Polyphen2 (35) variant predictors, which mainly use evolutionary conservation to assess the effect of each variant.

The effect of variant rs12329760 was further assess using: i. CONDEL (36) , which reports a weighted average of the scores from fatHMM and MutationAssessor, and ii. FoldX5 force field (37) , which calculates the stability of a protein based on the estimation of its free energy.

A ΔΔG> 0.5 kcal/mol (calculated as: ΔΔG= ΔG wt -ΔG mut ) was predicted to have a destabilizing effect. DNA extraction, genotyping and quality control have been described in detail previously (8) .

Genetic ancestry was inferred using ADMIXTURE and reference individuals from the 1000 Genomes project. Imputation was performed using the TOPMed reference panel.

Human embryonic kidney 293T cells (293Ts; ATCC) were maintained in Dulbecco's modified Eagle's medium (DMEM), 10% foetal calf serum (FCS), 1% non-essential amino acids (NEAA), 1% penicillin-streptomycin (P/S). Human Caco-2 (ATCC HTB-37) and Calu-3 (ATCC HTB-55) were maintained in DMEM, 20% FCS, 1% NEAA, 1% P/S. All cell lines were maintained at 37 o C, 5% CO 2 .

Lentiviral pseudotype production was performed as previously described (24) (38) . Briefly, pseudovirus was generated by co-transfecting 293Ts with lentiviral packaging constructs pCSFLW (minimal HIV genome with firefly luciferase reporter), pCAGGs-GAGPOL (HIV FLAG was used as previously described (24) . TMPRSS2 expression plasmid was a kind gift from Roger Reeves (Addgene plasmid #53887; http://n2t.net/addgene:53887; RRID:Addgene_53887) (39) . Non-cleavable ACE2-FLAG and TMPRSS2 mutants were generated by overlap extension PCR or site-directed mutagenesis.

293Ts were co-transfected with FLAG-tagged, non-cleavable ACE2 and TMPRSS2, as previously described (24) . Briefly, confluent 10cm 2 dishes of 293T cells were co-transfected with 1µg each of TMPRSS2 and ACE2-FLAG. 24 hours later, cells were resuspended in fresh media and either spun down for lysis and western blot or added to 96 well plates along with pseudovirus. 24 hours later, media was refreshed and a further 24 hours later, cells were lysed with reporter lysis buffer (Promega), and luminescence (measured as relative luminescence units, RLU) was read on a FLUOstar Omega plate reader (BMF Labtech) using the Luciferase Assay System (Promega).

Cell pellets for western blot were lysed in RIPA buffer (150mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 50mM TRIS, pH 7.4) supplemented with an EDTA-free protease inhibitor cocktail tablet (Roche). Cell lysates were combined with 4x Laemmli buffer (Bio-Rad) with 10% β-mercaptoethanol and boiled for 5 minutes. Membranes were probed with mouse anti-tubulin (abcam; ab7291), rabbit anti-TMPRSS2 (abcam; ab92323) and/or mouse anti-FLAG (F1804, Sigma). Near infra-red (NIR) secondary antibodies, IRDye® 680RD Goat anti-mouse (abcam; ab216776) and IRDye® 800CW Goat anti-rabbit (abcam; ab216773) were subsequently used. Blots were imaged using the Odyssey Imaging System (LI-COR Biosciences). Densitometry was performed using ImageJ.

All reagents, cell lines and antibodies used in this study are commercially available and validation data are available on the manufacturers' websites.

Sample size: Critically ill Covid-19 patients, n=2244; random controls matched by ancestry from UK Biobank, n=11220. The sample size was determined pragmatically by the number of cases recruited during the first wave of the outbreak in the UK (as described in (8)). No randomization was performed. Blinding was not used in this study because the exposure (genotype) and outcome (ICU admission) are objective. Confounding was controlled by the use of covariates: age, sex, deprivation score and genetic ancestry (8) . The association between the TMPRSS2 rs12329760 variant and COVID-19 severity was assessed using logistic regression. Genetic associations in the GenOMICC/ISARIC 4C cohort were analysed as previously described (8) . Briefly, logistic regression with additive and recessive models was performed in PLINKv1.9, adjusting for sex, age, mean-centered age-squared, top 10 principal components (principal component analysis [PCA] performed to adjust for population stratification) and deprivation index decile based on UK postcode. Each major ancestry group alternative in the 100,000 Genomes control group was performed with mixed model association tests in SAIGE (v0.39) (40), including age, sex, age-squared, age-sex interaction and the first 20 principal components as covariates. Trans-ethnic meta-analysis of GenOMICC data for different ancestries was performed by METAL using an inversevariance weighted method and the P-value for heterogeneity was calculated with Cochran's Q-test for heterogeneity implemented in the same software (41) .

Additional publicly available genetic data were obtained from the COVID-19 Host Genetics Analyses used all data with the exclusion of the 23&Me study, for which full data were not publicly available. Meta-analysis in all cases was performed using a fixed effect, inverse variance-weighted model, either as a trans-ethnic meta-analysis or subsetted by ancestry group.

Data are presented as mean ± standard deviation. Log-normality was assessed using the Shapiro-Wilk test and QQ plot. A two-tailed Student's t-test was used to compare the means of two groups. One-way ANOVA was used to compare the means of more than two groups.

Colocalisation analysis for genetic associations was performed by an Approximate Bayes Factor approach using the package coloc version 5, in R 4.1.0 (43) . Summary statistics (beta and variance) were from GWAS data (8) and from lung eQTL data from GTex v8 (44) , in individuals of European ancestry. To reduce the likelihood of violation of the single causal variant assumption arising from multiple independent association signals, the analysis was restricted to a region extending to 5 kb upstream and downstream of the TMPRSS2 gene.

With the assumption that exactly one measured SNP in the region was causative for each trait, SNP-level priors (p1 and p2) of 1/(n SNPs) were used for the probability of association with each individual trait, with an arbitrary prior of 0.1 x p1 for p12, the SNP-level prior probability of association with both traits. Sensitivity analysis was performed to assess the impact of prior selection, comparing the selected priors to the more stringent default priors (10 -4 for p1 and p2, 10 -5 for p12), and varying the p12 range from p1 to p1 x p2.

Research ethics committees (Scotland 15/SS/0110, England, Wales and Northern Ireland:

19/WM/0247). Current and previous versions of the study protocol are available at genomicc.org/protocol. All participants gave informed consent.

The 

We extracted 377 TMPRSS2 genetic variants reported as loss of function (LoF), missense or inframe and indel in the database of population genetic variations GnomAD (v2.1.1). All variants passed quality filters in GnomAD. Nine variants flagged by GnomAD as carrying dubious annotation or quality were excluded. Forty variants were loss of function or indel and the remaining 328 were missense. All variants except for one (rs12329760 C>T) were very rare (MAF <0.001). We focused on missense variants and studied the evolutionary conservation of TMPRSS2 amino acids and the impact of amino acid substitution on TMPRSS2 protein structure (described in Methods). The first experimental structure of To assess whether the rs12329760 could be a proxy for an association with a nearby expression quantitative trait locus (eQTL), colocalisation analysis was performed to compare the GWAS signal at the locus to eQTL associations for TMPRSS2 and neighbouring gene MX1 in GTex version 8 (44) (Figure S3 A-C), using an Approximate Bayes Factor approach (43) . Under an assumption of a single causal variant within the locus for each trait, the posterior probability of a common causal variant was 1.1% for TMPRSS2 expression and 2.0% for MX1 expression, compared to posterior probabilities of 67% and 42% respectively for independent associations. Sensitivity analysis showed that the analysis was robust to choice of prior probabilities: more stringent software-default single-trait priors increased the posterior probabilities of null or single-trait-only association hypotheses, but had little impact on the colocalisation probability (1.1% for TMPRSS2 and 0.2% for MX1); varying prior probability for colocalisation ( Figure S3 D-F) had an impact only when approaching the prior for single-trait associations, and did not result in posterior probabilities for colocalisation exceeding those for separate associations. Although independent contributions from multiple variants towards the genetic association cannot be excluded, this indicates that any genetic association between rs12327960 and severe COVID-19 is unlikely to be attributable to linkage disequilibrium with an eQTL and, thus, modification of protein function is more likely. cases from the metanalyses previously described) or with a self-reported or physicianconfirmed COVID diagnosis (total n=112,443 cases, Figure 2 , panel A).

Although these meta-analyses include UK Biobank data and all except the hospitalised versus non-hospitalised comparison include data from the GenOMICC/ISARIC 4C cohort, and thus do not provide completely independent replication, these cohorts only comprise less than 25% of the total cases, limiting the impact of this single study on the overall results. These data therefore provide further support for our hypothesis that the TMPRSS2 rs12329760 variant has a protective effect against severe and/or life-threatening COVID-19. However, studies examining the prevalence of this variant in SARS-CoV-2 infected asymptomatic or paucisymptomatic individuals are needed to ascertain its protective effect against mild viral infection.

To investigate the phenotypic effect of the TMPRSS2 V160M variant, we co-transfected 293Ts cells, which we have previously confirmed that they do not endogenously express ACE2 or TMPRSS2 (24) , with ACE2 and either TMPRSS2 wild type (TMPRSS2 WT ) or V160M (TMPRSS2 V160M ), as previously described (24) . We and others previously observed that co-expression of TMPRSS2 and ACE2 results in rapid cleavage of ACE2. We, therefore, used a mutant ACE2 that is more poorly degraded by TMPRSS2 (49) . Two additional TMPRSS2 variants were included as controls: the catalytically inactive S441A (TMPRSS2 S441A ) and the catalytically active R255Q (TMPRSS2 R255Q ), that is unable to autocleave (16) . First, we investigated the autocleavage pattern of the different TMPRSS2 Overall, these data suggest the V160M substitution exerts a partial inhibitory effect on the proteolytic autocleavage of TMPRSS2 (see Figure 3A -D, Supplementary Figure S4 ). Subsequently, we investigated the effect of TMPRSS2 V160M on promoting viral entry, using a previously described SARS-CoV-2 pseudovirus entry assay (24) . Pseudovirus expressing the glycoprotein from the vesicular stomatitis virus (VSV-G) was used as a control, as this virus enters cells in a TMPRSS2-independent manner (24) . Briefly, cells co-transfected with ACE2 and TMPRSS2 wild type or variants were incubated with the pseudovirus (as described in (24) , (38) ) and, after 48h, luminescence was measured. TMPRSS2 WT enhanced viral entry by ~5-fold compared to empty vector, while the catalytically dead TMPRSS2 S441A showed no enhancement ( Figure 3E ). The non-autocleavable mutant TMPRSS2 R255Q showed similar enhancement, suggesting that autocleavage is dispensable for optimal TMPRSS2-mediated enhancement. TMPRSS2 V160M showed no significant difference in viral entry compared to the TMPRSS2 WT . Overall, the expression of catalytically active TMPRSS2 proteins only slightly inhibited VSV-G mediated entry ( Figure 3F ).

The partial inhibitory effect exerted by the V160M variant on the proteolytic autocleavage of TMPRSS2 resulted in a far greater proportion of uncleaved, surface-expressed TMPRSS2 V160M compared to TMPRSS2 WT . We compared this autocleavage seen in transfected 293T cells, to that seen in several epithelial cell lines that naturally express endogenous ACE2 and TMPRSS2 (24) This again suggests that the high levels of autocleavage seen in 293T cells may be, in part, an artefact of overexpression (Supplementary Figure S5) . Therefore, we re-assessed whether TMPRSS2 V160M affects SARS-CoV-2 S-expressing pseudovirus entry by using the double mutant TMPRSS2 R255Q/V160M (which does not autocleave and is, therefore, more similar to endogenous TMPRSS2 in Calu-3 and Caco-2 cells), to control for protein cell-surface expression. Under these conditions, and across a range of plasmid titrations of both TMPRSS2 mutants and ACE2, TMPRSS2 R255Q/V160M showed a significantly reduced ability to promote SARS-CoV-2 S-expressing pseudovirus compared to TMPRSS2 R255Q alone, despite equal protein expression (Figure 4 A,C,D,F). Again, TMPRSS2 R255Q/V160M had no effect on VSV-G-mediated entry (Figure 4 B,E).

Overall, our results suggest that the rs12329760 C>T variant results in a moderately less catalytically active TMPRSS2, which is less able to autocleave and prime the SARS-CoV-2 spike protein. This may explain the protective effect against life-threatening COVID-19 observed in our cohort of patients admitted to ICU, compared to the general population. Such an effect was more prominent in homozygotes (recessive model) for the rs12329760 C>T in whom a 30% (OR 0.70) risk reduction was observed. Unfortunately, we did not have samples from asymptomatic/pauci symptomatic patients, but data from COVID-19hg meta-analyses appear to suggest that the rs12329760 variant has no protective effect against SARS-Co-V2 The pharmacological inhibition of TMPRSS2 using serine protease inhibitors, such as camostat and nafamostat, has been proposed as a pharmacological treatment of COVID-19 patients. In vitro (12) and animal studies have demonstrated that camostat can block viral entry (reviewed in (52)), and initial reports on the repurposing of camostat in COVID-19 patients have provided promising results (53) . However, a recently completed clinical trial using camostat in patients hospitalized for severe COVID-19, did not demonstrate a significant reduction in time-to-clinical improvement compared to placebo (54) . As the authors suggest, these patients were likely to have passed the most active stage of viral replication at the time of treatment and were in the hyper-inflammatory stage of the COVID-19, thus possibly explaining the lack of camostat efficacy. Several additional clinical trials of camostat in COVID-19 are currently underway (29) . Recently, the placebo-controlled phase III trial conducted in Japan on pauci symptomatic COVID-19 patients administering camostat mesilate 600mg 4 times a day did not meet its primary end point of time to negative Sars-CoV-2 test (55), however data on secondary end points, such as progression to severe or lifethreatening COVID-19, are still not publicly available.

Very little is known on TMPRSS2 and further extensive in vitro and in vivo studies on its pathophysiology are necessary. Since the beginning of the COVID-19 pandemic, the interest in TMPRSS2 has focused only on its role as a serine protease involved in the activation of the SARS-CoV-2 spike protein. However, as a soluble protease, TMPRSS2 may have additional substrates, and in vitro studies have demonstrated that PAR2 is one of these substrates (56) , (57) . PAR2 is expressed in several tissues, including lung, vascular endothelial and vascular smooth muscle cells (58) (59) and its protease-mediated activation promotes inflammation by inducing prostaglandin synthesis and cytokine production in the lungs and other organs (60)(61)(62)(63) (64) . An intriguing hypothesis is that, similar to other soluble serine proteases, such as the human airway trypsin-like protease HAT (also known as TMPRSS11D), the soluble wild type TMPRSS2 protease may also have a role in promoting inflammation in the lungs and other tissues.

Since May 2020, when we reported the TMPRSS2 variant rs12329760 as possibly damaging to protein structure/function and raised the possibility that it could partly explain host susceptibility to COVID-19 severity (65), several other studies have also supported this hypothesis (66)(67)(68)(69)(70)(71) . In this study we have confirmed our initial hypothesis and provided a mechanistic effect to explain how this variant may contribute to the host susceptibility to severe COVID-19.

As previously discussed, one limitation of our study was the lack of access to a cohort of asymptomatic/pauci symptomatic COVID-19 patients. In the absence of such a cohort, we considered the general population as a good proxy and used this for comparison with COVID-19 severe cases. Indeed, a recent systematic review and metanalysis shows that one third of COVID-19 positive cases do not develop symptoms (72) . When well-characterized cohorts of asymptomatic/pauci symptomatic COVID-19 patients become available, it will be possible to further investigate the role of TMPRSS2 variant rs12329760 on Sars-Co-V2 infection. Another limitation of this study is that we did not directly validate our results in endogenously expressing cell lines, such as like Calu-3, as this would require gene editing the endogenous TMPRSS2. Calu-3 cells are extremely slow growing and highly resistant to single cell cloning, thus making this cell line not particularly suitable for gene editing. The TMPRSS2 protein is composed of a cytoplasmic region (residues 1-84), a transmembrane region (TM, residues 85-105) and an extracellular region (residues 106-492).

The latter is composed of three domains: the LDLR class A (residues 112-149), the scavenger receptor cysteine-rich domain (SRCR) (residues 150-242) and the Peptidase S1 (residues 256-489), which contains the protease active site: residues His296, Asp345 and Ser441. The threedimensional structure of the extracellular region residues 145-491 corresponding to domains SRCR-2 (in green) and Peptidase S1 (in blue) is presented. Valine 160 (Val 160, depicted as a red sphere on the cartoon), which harbours variant p.Val160Met, occurs in the SRCR domain and spatially far from the TMPRSS2 catalytic site (mapped onto the surface of TMPRSS2). µg values indicate the amount of TMPRSS2 or ACE2 plasmid added to each condition. RLU, relative luminescence units.

*, 0.05 ≥ P > 0.01; **, 0.01 ≥ P > 0.001, ***, 0.001 ≥ P

COVID-19) Dashboard

Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis

Life-Threatening COVID-19: Defective Interferons Unleash Excessive Inflammation

Genomewide Association Study of Severe Covid-19 with Respiratory Failure

Association between ABO blood groups and COVID-19 infection, severity and demise: A systematic review and meta-analysis

Inborn errors of type I IFN immunity in patients with life-threatening COVID-19

Autoantibodies against type I IFNs in patients with life-threatening COVID-19

Genetic mechanisms of critical illness in Covid-19

Evidence that TMPRSS2 activates the severe acute respiratory syndrome coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune response

Efficient activation of the severe acute respiratory syndrome coronavirus spike protein by the transmembrane protease TMPRSS2

A transmembrane serine protease is linked to the severe acute respiratory syndrome coronavirus receptor and activates virus entry

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Cell entry mechanisms of SARS-CoV-2

Prostatelocalized and androgen-regulated expression of the membrane-bound serine protease TMPRSS2

TMPRSS2 Is the Major Activating Protease of Influenza A Virus in Primary Human Airway Cells and Influenza B Virus in Human Type II Pneumocytes

Catalytic cleavage of the androgen-regulated TMPRSS2 protease results in its secretion by prostate and prostate cancer epithelia

SARS-CoV-2 receptor ACE2 and TMPRSS2 are primarily expressed in bronchial transient secretory cells

Expression of transmembrane serine protease TMPRSS2 in mouse and human tissues

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Expression of the SARS-CoV-2 Entry Proteins, ACE2 and TMPRSS2, in Cells of the Olfactory Epithelium: Identification of Cell Types and Trends with Age

Age-determined expression of priming protease TMPRSS2 and localization of SARS-CoV-2 in lung epithelium

TMPRSS2 Contributes to Virus Spread and Immunopathology in the Airways of Murine Models after Coronavirus Infection

Distinct mechanisms for TMPRSS2 expression explain organ-specific inhibition of SARS-CoV-2 infection by enzalutamide

The furin cleavage site in the SARS-CoV-2 spike protein is required for transmission in ferrets

Simultaneous treatment of human bronchial epithelial cells with serine and cysteine protease inhibitors prevents severe acute respiratory syndrome coronavirus entry

SARS-CoV-2 entry into human airway organoids is serine proteasemediated and facilitated by the multibasic cleavage site. Elife

Protease inhibitors targeting coronavirus and filovirus entry

Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity. EBioMedicine

The Phyre2 web portal for protein modeling, prediction and analysis

UniProt: the universal protein knowledgebase

Highly accurate protein structure prediction with AlphaFold

Can Predicted Protein 3D Structures Provide Reliable Insights into whether Missense Variants Are Disease Associated?

SIFT missense predictions for genomes

A method and server for predicting damaging missense mutations

Improving the assessment of the outcome of nonsynonymous SNVs with a consensus deleteriousness score, Condel

The FoldX web server: an online force field

Selfamplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice

Survey of Human Chromosome 21 Gene Expression Effects on Early Development in Danio rerio. G3 (Bethesda)

Efficiently controlling for case-control imbalance and sample relatedness in large-scale genetic association studies

METAL: fast and efficient meta-analysis of genomewide association scans

COVID-19 Host Genetics Initiative. Mapping the human genetic architecture of COVID-19

Bayesian test for colocalisation between pairs of genetic association studies using summary statistics

Enhancing GTEx (eGTEx) groups, NIH Common Fund, NIH/NCI, et al. Genetic effects on gene expression across human tissues

CD6-ligand interactions: a paradigm for SRCR domain function? Immunol Today

An ancient, highly conserved family of cysteine-rich protein domains revealed by cloning type I and type II murine macrophage scavenger receptors

The SRCR superfamily: a family reminiscent of the Ig superfamily

The National Genomic Research Library v5.1, Genomics England

TMPRSS2 and ADAM17 cleave ACE2 differentially and only proteolysis by TMPRSS2 augments entry driven by the severe acute respiratory syndrome coronavirus spike protein

Apparent difference in fatalities between Central Europe and East Asia due to SARS-COV-2 and COVID-19: Four hypotheses for possible explanation

Initial whole-genome sequencing and analysis of the host genetic contribution to COVID-19 severity and susceptibility

Camostat mesylate against SARS-CoV-2 and COVID-19-Rationale, dosing and safety

Camostat mesylate therapy in critically ill patients with COVID-19 pneumonia

Efficacy of the TMPRSS2 inhibitor camostat mesilate in patients hospitalized with Covid-19-a double-blind randomized controlled trial

Foipan dropped as potential coronavirus treatment

The membrane-anchored serine protease, TMPRSS2, activates PAR-2 in prostate cancer cells

TMPRSS2, a novel membrane-anchored mediator in cancer pain

Characterization of protease-activated receptor-2 immunoreactivity in normal human tissues

A protective role for protease-activated receptors in the airways

The role of protease activation of inflammation in allergic respiratory diseases

Protease-activated receptors (PARs): mechanisms of action and potential therapeutic modulators in PAR-driven inflammatory diseases

Protease-activated receptor-2 activation induces acute lung inflammation by neuropeptidedependent mechanisms

Human airway trypsin-like protease stimulates human bronchial fibroblast proliferation in a protease-activated receptor-2-dependent pathway

Human airway trypsin-like protease increases mucin gene expression in airway epithelial cells

Structure, function and variants analysis of the androgen-regulated TMPRSS2, a drug target candidate for COVID-19 infection

Why does SARS-CoV-2 hit in different ways? Host genetic factors can influence the acquisition or the course of COVID-19

Structural Variability, Expression Profile, and Pharmacogenetic Properties of TMPRSS2 Gene as a Potential Target for COVID-19 Therapy. Genes (Basel)

Variability in genes related to SARS-CoV-2 entry into host cells (ACE2, TMPRSS2, TMPRSS11A, ELANE, and CTSL) and its potential use in association studies

New insights into genetic susceptibility of COVID-19: an ACE2 and TMPRSS2 polymorphism analysis

First comprehensive computational analysis of functional consequences of TMPRSS2 SNPs in susceptibility to SARS-CoV-2 among different populations

Assessment of risk conferred by coding and regulatory variations of TMPRSS2 and CD26 in susceptibility to SARS-CoV-2 infection in human

Asymptomatic SARS-CoV-2 infection: A systematic review and metaanalysis